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Fatty-acid synthesis in bacteria is of great interest as a target
for the discovery of antibacterial compounds. The addition of
a new acetyl moiety to the growing fatty-acid chain, an
essential step in this process, is catalyzed by -ketoacyl-ACP
synthase (KAS). It is inhibited by natural antibiotics such as
cerulenin and thiolactomycin; however, these lack the
requirements for optimal drug development. Structure-based
biophysical screening revealed a novel synthetic small
molecule, 2-phenylamino-4-methyl-5-acetylthiazole, that binds
to Escherichia coli KAS I with a binding constant of 25 mM as
determined by ﬂuorescence titration. A 1.35 A ˚ crystal
structure of its complex with its target reveals noncovalent
interactions with the active-site Cys163 and hydrophobic
residues of the fatty-acid binding pocket. The active site is
accessible through an open conformation of the Phe392 side
chain and no conformational changes are induced at the active
site upon ligand binding. This represents a novel binding mode
that differs from thiolactomycin or cerulenin interaction. The
structural information on the protein–ligand interaction offers
strategies for further optimization of this low-molecular-
weight compound.
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1. Introduction
Antibacterial therapeutics are of great medical importance
and have saved countless human lives in past decades. Owing
to the rise in drug resistance amongst major human pathogens
in recent years, there is an urgent need for antibiotics with
novel mechanisms of action (Barrett & Barrett, 2003). One
promising target for the discovery of such new antibacterial
therapeutics is the biosynthesis of fatty acids in bacteria
(Heath et al., 2001; Payne, 2004). Fatty-acid biosynthesis is an
essential and highly conserved enzymatic process. The
growing fatty-acid chain is shuttled between the catalytic
functionswhile bound to a small acylcarrierprotein (ACP) via
a phosphopantetheine linker. The high degree of conservation
in fatty-acid biosynthesis creates the potential for a genuinely
broad-spectrum antibiotic. On the other hand, signiﬁcant
differences between prokaryotic and eukaryotic (and in
particular mammalian) fatty-acid biosynthesis will allow the
necessary differentiation towards the prokaryotic target. In
prokaryotes the series of catalytic steps for fatty-acid bio-
synthesis is performed by individual enzymes (type II fatty-
acid biosynthesis; Rock & Jackowski, 2002), while in mammals
all the required catalytic functions are united on a large single
polypeptide chain (type I fatty-acid biosynthesis; Smith et al.,
2003). The success of fatty-acid biosynthesis as an antibacterial
target is exempliﬁed by triclosan, a chlorinated bisphenol that
selectively inhibits bacterial enoyl-ACP reductase. It has been
in use for decades as an additive in many consumer productsowing to its bactericidal properties (Bhargava & Leonard,
1996).
Another highly interesting target within the fatty-acid
biosynthetic pathway is -ketoacyl-ACP synthase (KAS;
Khandekar et al., 2003). This enzyme catalyses the Claisen
condensation reaction, i.e. carbon–carbon bond formation
upon the addition of a new acetyl unit to the growing fatty-
acid chain (Heath & Rock, 2002). The reaction can be divided
into three distinct steps: (i) transfer of the acyl group from
acyl-ACP to the active-site cysteine residue, resulting in a
thioester, (ii) binding of malonyl-ACP and subsequent
decarboxylation to form a carbanion and (iii) nucleophilic
attack of the carbanion on the carbonyl carbon of the thioester
to form the carbon–carbon bond. The functional oligomer of
the KAS protein is the homodimer, with residues from both
monomers being involved in each fatty-acid-binding pocket
(Edwards et al., 1997; Huang et al., 1998; Olsen et al., 1999).
Three related but distinct enzymes with KAS activity are
found in Escherichia coli and some other bacteria (KAS I, II
and III, also known as FabB, FabF and FabH, respectively;
Heath & Rock, 2002). KAS I and KAS III are essential
enzymes in E. coli, in contrast to KAS II (Rosenfeld et al.,
1973; Garwin et al., 1980; Lai & Cronan, 2003).
Several novel inhibitors of bacterial KAS III protein have
recently been reported (He & Reynolds, 2002; Daines et al.,
2003; He et al., 2004; Nie et al., 2005), highlighting the ongoing
efforts to target novel antibacterial drugs against KAS activity.
KAS I is a particularly attractive target as it has already been
validated through the action of two compounds from natural
sources: cerulenin and thiolactomycin (Fig. 1). Both inhibit
KAS I and KAS II but not KAS III activity (Price et al., 2001).
Cerulenin (from Cephalosporium caerulens) has a reactive
epoxy group that forms a covalent adduct with the active-site
cysteine of KAS (Price et al., 2001; Vance et al., 1972;
D’Agnolo et al., 1973; Moche et al., 1999). It is not a selective
antibacterial, however, since it also inhibits the KAS function
of the mammalian FAS multienzyme complex. The second
compound, thiolactomycin, is a thiolactone from actino-
bacteria (Nocardia sp.) that reversibly inhibits bacterial KAS
(Price et al., 2001; Nishida et al., 1986). It is active against a
wide range of bacteria and other pathogens such as plasmodia
and trypanosomes (Noto et al., 1982; Waller et al., 1998; Morita
et al., 2000). It does not affect mammalian fatty-acid bio-
synthesis (Hayashi et al., 1983) and in mice it protects against
infections without toxic side effects (Miyakawa et al., 1982).
However, problems in synthesis and with stability have
prevented its use as an antibiotic drug (Heath et al., 2001).
Thiolactomycin-derived compounds with improved properties
are currently being explored as inhibitors of bacterial and
mammalian KAS (Sakya et al., 2001; Douglas et al., 2002;
McFadden et al., 2005). Recently, a novel compound from a
natural source, platensimycin, was discovered to be a potent
inhibitor of bacterial KAS I and KAS II, with antibiotic
properties in animal models (Wang et al., 2006). However, it
remains challenging to develop such complex natural products
into drug molecules with the required efﬁcacy, synthetic access
and pharmacological properties.
Here, we describe for the ﬁrst time a small synthetic
compound that binds to the KAS I active site. The interaction
of this aminothiazole derivative with E. coli KAS I has an
equilibrium dissociation constant of 25 mM. A high-resolution
crystal structure of the protein–ligand complex at 1.35 A ˚ could
be obtained after optimization of the buffer conditions in
order to improve the solubility of the ligand. The structure
provides insights into the binding mode and suggests strategies
for further optimization of this inhibitor.
2. Materials and methods
2.1. Binding assay and ligand solubility by analytical
ultracentrifugation
Sedimentation-equilibrium runs were performed at a rota-
tional speed of 16 000 rev min
1 at 293 K using a Beckman–
Coulter Optima XL-I analytical ultracentrifuge. An eight-hole
rotor ﬁtted with six-channel Alu-ﬁlled Epon analytical cells
was used. The reference channels were ﬁlled with 120 ml
binding-assay buffer (20 mM HEPES pH 7.5, 200 mM NaCl,
2m M TCEP, 0.5 mM EDTA), whereas the sample channels
were ﬁlled with 100 ml buffer solution containing 22.7 mM
(1 mg ml
1) E. coli KAS I and 100 mM ligand. Cells with
protein and ligand alone at the above concentrations were also
spun as a control. After 20 h, a radial absorbance proﬁle was
recorded at 280 nm. A further recording taken 2 h later
proved that equilibrium had been reached. Equilibrium
absorbance proﬁles were then recorded at the speciﬁc wave-
lengths of the studied ligands.
Analysis of the proﬁles was performed using the program
DISCREEQ (Schuck, 1994). Analysis of the optical density at
the ligand characteristic wavelength yields, with the help of the
absorption coefﬁcient, the amount of bound ligand, the
stoichiometry, the free ligand concentration through baseline
analysis and ligand-induced protein precipitation if it occurs.
The baseline was experimentally determined at 40 000 rev min
1.
The ligand absorption coefﬁcients were determined from
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Figure 1
Structures of cerulenin, thiolactomycin and 2-phenylamino-4-methyl-5-
acetylthiazole.absorption spectra recorded on an Uvikon 930 spectro-
photometer. The absorption coefﬁcient of the protein at
280 nm was calculated from the amino-acid sequence. For
other wavelengths it was derived from a wavelength scan
recorded at 3000 rev min
1 at the beginning of the equilibrium
experiment.
The radial absorbance proﬁles of the low-molecular-weight
aminothiazole compound were recorded at 380 nm. At this
wavelength only the compound was detected, the protein
absorption being negligible. In this case, visual inspection of
the recorded absorbance proﬁle readily revealed binding
because at the chosen speed the proﬁle for the ligand alone is
ﬂat (Fig. 2b).
Ligand solubility in the buffer of interest was assessed by
recording the sedimentation equilibrium in a further higher
speed run (40 000 rev min
1) for a channel containing the
ligand alone. The solubility was calculated from the area under
the absorbance proﬁle at the ligand speciﬁc wavelength, which
was 380 nm for the aminothiazole (data not shown).
2.2. Fluorescence titration
Fluorescence titration was performed at 293 K in binding-
assay buffer using an SLM-AMINCO 8100 double-grating
spectroﬂuorometer. The protein concentration was 4.9 mM.
Small aliquots of known ligand concentration were added and
the ﬂuorescence, excited at 280 nm, was recorded at 340 nm.
The ﬂuorescence intensity was corrected for protein dilution
and for the ﬁlter effect (Birdsall et al., 1983). The corrected
ﬂuorescence intensity was plotted against the ligand concen-
tration and ﬁtted using a four-parameter sigmoidal function,
from which the equilibrium dissociation constant Kd was
computed using the law of mass action assuming a 1:1 protein–
ligand complex (Eftink, 1997).
2.3. Cloning, expression, purification and crystallization
The cloning, expression and puriﬁcation of E. coli KAS I
was performed essentially as described previously (Edwards et
al., 1997). Brieﬂy, the gene for E. coli KAS I was ampliﬁed
from genomic E. coli DNA and cloned into the vector pQE-80
via BamHI and SalI. The protein construct with an N-terminal
His tag was expressed in E. coli M15 strain. The expression
yield was high, with about 50% of the E. coli KAS I present in
the soluble supernatant. Efﬁcient puriﬁcation of E. coli KAS I
was achieved using immobilized metal-afﬁnity chromato-
graphy (IMAC; Ni–NTA matrix) and size-exclusion chroma-
tography (SEC; S75 matrix). Puriﬁcation progress was
assessed using SDS–PAGE. The puriﬁed protein was
concentrated to 70 mg ml
1 in20 mM HEPES pH 7.5, 200 mM
NaCl, 2 mM TCEP, 0.5 mM EDTA, ﬂash-frozen in liquid
nitrogen in 200 ml aliqouts and stored at 193 K. E. coli KAS I
was crystallized at room temperature in a hanging-drop
experiment with 1.9 M ammonium sulfate, 3% PEG 400 and
0.1 M Tris–HCl pH 7.5 as precipitant (Olsen et al., 1995). The
protein concentration was 70 mg ml
1 in 20 mM HEPES pH
7.5, 200 mM NaCl, 2 mM TCEP, 0.5 mM EDTA. The mixing
ratio of buffer to protein was 2:1. Crystals appeared after 1–2 d
and grew to full size after a few days. Crystals were soaked
with thiolactomycin for 16–24 h after transfer into 2.3 M
ammonium sulfate, 0.1 M Tris–HCl pH 7.5, 0.3 mM thio-
lactomycin, 3% DMSO. For soaking with the aminothiazole
under PEG 8000 conditions, a 20 ml drop of 30% PEG 8000,
0.1 M ammonium sulfate, 0.1 M Tris–HCl pH 7.5, 5 mM TCEP
was equilibrated overnight in a hanging-drop setup against
0.5 ml 2.3 M ammonium sulfate, 0.1 M Tris–HCl pH 7.5. The
aminothiazole compound was added to the drop to 5 mM from
a 100 mM DMSO stock (5% residual DMSO) and crystals
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Figure 2
(a) Fluorescence titration of the aminothiazole ligand against E. coli KAS
I protein. The protein concentration was 4.9 mM in binding-assay buffer
(20 mM Tris pH 7.5, 200 mM NaCl, 1 mM TCEP, 0.5 mM EDTA). The
excitation and emission wavelengths were 280 and 340 nm, respectively.
Owing to the high absorption coefﬁcient of the compound at 340 nm, the
efﬁcient dipole–dipole interaction strongly quenched the emission of
both tryptophan residues of the protein. Circles show the ﬂuorescence
intensity in arbitrary units after correction for ﬁlter effects; the line shows
a sigmoidal ﬁt resulting in an equilibrium dissociation constant Kd of
25 mM.( b) Sedimentation equilibrium of the aminothiazole compound in
the absence and presence of E. coli KAS I. The absorbance proﬁles were
recorded at 16 000 rev min
1 at 380 nm for 100 mM aminothiazole in the
absence or presence of 22.7 mM E. coli KAS I. At this wavelength the
absorbance of the protein is negligible, so that only the ligand was
detected. The ligand alone showed a ﬂat radial proﬁle for this rotational
speed (triangles). In the presence of E. coli KAS I the radial
concentration proﬁle corresponds to the protein molar mass, demon-
strating binding of the ligand (circles).were soaked in this drop for 16–24 h. For the apo structure
from PEG 8000 conditions, DMSO without the aminothiazole
was added to the drop to 5% and the TCEP was omitted from
the drop. Crystals were frozen in 2.3 M ammonium sulfate,
0.1 M Tris–HCl pH 7.5, 25% glycerol for the ammonium
sulfate conditions and directly from the drop for the PEG 8000
conditions.
2.4. Data collection, processing and refinement
Diffraction data for all data sets were collected at 120 K at
the Swiss Light Source (SLS), Villigen, Switzerland. The
diffraction images were processed using XDS and scaled with
XSCALE (Kabsch, 1993). No signiﬁcant difference in unit-cell
parameters was observed between crystals soaked in the
ammonium sulfate and PEG 8000 conditions (Table 1). The
structure was solved by molecular replacement using E. coli
KAS I (PDB code 1ek4; Olsen et al., 2001) as a model. Rigid-
body reﬁnement of the four monomers followed by restrained
reﬁnement in REFMAC (Murshudov et al., 1999; Collabora-
tive Computational Project, Number 4, 1994) and ARP/wARP
v.5.0 (Perrakis et al., 1999) was used for reﬁnement and to add
water molecules to the model. Ligand building in the Fo  Fc
difference electron-density maps and manual rebuilding were
performed with MOLOC (Gerber, 1992). The high resolution
of the data sets (1.35–1.60 A ˚ ) enabled the reﬁnement of
alternative side-chain conformations for several side chains.
Final reﬁnement was performed without noncrystallographic
symmetry (NCS) restraints. Indi-
vidual isotropic B factors were
reﬁned in REFMAC for all data
sets, with the exception of the
structure with aminothiazole
ligand bound. Here, individual
anisotropic B factors were intro-
duced in the ﬁnal round of
reﬁnement, resulting in a
decrease in Rfree from 0.179 to
0.151. The reﬁnement statistics
are reported in Table 1. Figures
were prepared using PyMOL
(DeLano, 2002).
2.5. Molecular modelling
ROCS v.2.1.1 (Rapid Overlay of
Chemical Structures, Openeye
Scientiﬁc Software) was applied
in order to investigate the shape
and chemical similarity of the
aminothiazole compound and
thiolactomycin. The conformation
of thiolactomycin was taken from
the E. coli KAS I–thiolactomycin
crystal structure. For the amino-
thiazole compound, OMEGA
v.1.8.1 (Openeye Scientiﬁc Soft-
ware) was used to generate
multiple low-energy conformations. Default settings were
used in the ROCS and OMEGA calculations, except for
turning on the ImplicitMillsDean ﬂag for the colour score in
ROCS. The ﬁnal scores derived were a shape Tanimoto score
for shape similarity (between 0 and 1) and a scaled colour
score for chemical similarity (between 0 and 1). FRED v.1.2.10
(Fast Rigid Exhaustive Docking, Openeye Scientiﬁc Software)
was used as a docking tool to investigate the binding mode of
the aminothiazole compound to E. coli KAS I. Docking was
performed using the structure of the apoprotein with water
molecules removed. The binding site was deﬁned as a box
around the positions of thiolactomycin and cerulenin and
increased by 2 A ˚ . ChemScore was used as a scoring function.
3. Results and discussion
3.1. Identification of novel molecules for the inhibition of
E. coli KAS I
For the E. coli KAS I protein, structural information is
available for the apoprotein and for several protein–inhibitor
complexes (Olsen et al., 1999, 2001; Price et al., 2001). Based
on this knowledge, an in silico screening was performed with
the goal of identifying novel hits for exploration in a drug-
discovery program. About 100 hits were selected based on
compound availability, synthetic feasibility and drug-likeness
to be tested experimentally for binding to E. coli KAS I by
analytical ultracentrifugation. This method is independent of
research papers
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Table 1
Data-collection and reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
Apo in
(NH4)2SO4
Apo in
PEG 8000
Thiolactomycin
in (NH4)2SO4
Aminothiazole
in PEG 8000
PDB code 2vb9 2vb7 2vb8 2vba
Data collection
Space group P212121 P212121 P212121 P212121
Unit-cell parameters
a (A ˚ ) 58.9 59.1 59.1 59.0
b (A ˚ ) 138.4 139.5 138.4 139.5
c (A ˚ ) 211.9 212.2 212.0 212.2
 =  =  ()9 0 9 0 9 0 9 0
Resolution (A ˚ ) 20–1.50 (1.60–1.50) 20–1.60 (1.70–1.60) 20–1.50 (1.60–1.50) 20–1.35 (1.45–1.35)
Rmerge 7.5 (48.4) 7.4 (22.3) 6.1 (37.2) 5.8 (20.4)
I/(I) 12.0 (3.0) 10.9 (5.3) 14.2 (3.5) 13.5 (6.2)
Completeness (%) 99.4 (98.0) 95.0 (75.4) 95.8 (78.0) 92.3 (72.9)
Redundancy 7.1 (6.1) 6.9 (4.2) 6.3 (5.4) 6.8 (5.2)
Reﬁnement
Resolution (A ˚ ) 20–1.50 20–1.60 20–1.50 20–1.35
No. of reﬂections 262111 210551 253711 337314
Rwork/Rfree 19.7/23.8 15.6/18.6 15.1/18.5 11.9/15.1
No. of atoms
Total 14240 14475 14649 14386
Protein 11903 11947 11946 11939
Ligand — — 56 16
Water/ion 2333 2528 2645 2430
B factors (A ˚ 2)
Overall 20.2 17.9 16.8 17.5
Protein 17.5 14.9 13.5 14.6
Ligand — — 16.1 26.3
Water/ion 36.2 33.7 34.0 33.3
R.m.s. deviations
Bond lengths (A ˚ ) 0.015 0.012 0.015 0.014
Bond angles () 1.53 1.36 1.50 1.58the biochemistry of the target, requires essentially no target-
speciﬁc assay development, has no requirements for labelling
or immobilization methods and has a moderate throughput of
20–30 compounds per day. For one of the compounds, an
aminothiazole derivative (2-phenylamino-4-methyl-5-acetyl-
thiazole; Fig. 1), a clear sign of co-sedimentation with the
protein was detected. The binding afﬁnity of this novel ligand
to E. coli KAS I was further evaluated by ﬂuorescence titra-
tion. Upon addition of the aminothiazole ligand to the protein
in solution, the inherent tryptophan ﬂuorescence of the
protein was quenched, reﬂecting population of the ligand–
protein complex (Fig. 2a). The titration curve yields an equi-
librium dissociation constant (Kd)o f2 5mM for binding of the
novel aminothiazole ligand to the E. coli KAS I protein. The
afﬁnity of this compound is similar to those of the known
reference inhibitors thiolactomycin (25 mM) and cerulenin
(3 mM) (Price et al., 2001). Further characterization of the
complex was achieved by analytical ultracentrifugation
experiments. Comparison of the sedimentation equilibrium of
the ligand and of a mixture of ligand and protein shows a clear
indication of complex formation (Fig. 2b). In addition, the
solubility of the aminothiazole derivative was determined to
be at least 100 mM in the buffer used for the binding assay.
3.2. Crystallization of E. coli KAS I with bound
aminothiazole ligand
Crystallographic structure determination of E. coli KAS I
with bound aminothiazole ligand was used to obtain molecular
details of the interactions with its target. E. coli KAS I was
prepared and crystallized as described previously (Olsen et al.,
1999). A cocrystallization method was reported in the struc-
ture determination of E. coli KAS I with inhibitors (Price et
al., 2001), but crystal soaking allows more efﬁcient screening
of a large number of compounds. Consequently, we estab-
lished a soaking procedure for the crystals of E. coli KAS I
with the reference inhibitor thiolactomycin. The resulting
Fo  Fc electron-density map from a data set at 1.5 A ˚ (Table 1)
clearly conﬁrmed binding of thiolactomycin at the active site.
However, when crystal soaking was performed with the
aminothiazole compound, the Fo  Fc map from a 1.6 A ˚ data
set showed only weak additional density around the active site
that proved difﬁcult to interpret, despite the similar afﬁnities
of thiolactomycin and the aminothiazole compound of around
25 mM. We assume that the weak binding under crystal-
soaking conditions was a consequence of the low solubility of
the aminothiazole compound of 4.8 mM at the high ionic
strength of the crystal soaking buffer (20 mM Tris pH 7.5,
2.3 M ammonium sulfate, 1% DMSO) compared with at least
100 mM at low ionic strength as used in the assay buffer.
Therefore, a new soaking system was evaluated with better
solubility conditions. Finally, 30% PEG 8000 proved to be a
good low ionic strength surrogate for ammonium sulfate in the
crystal-soaking buffer that had no adverse effect on diffraction
quality after crystal soaking; a solubility of at least 100 mM was
conﬁrmed for this buffer condition (30% PEG 8000, 0.1 M
ammonium sulfate, 0.1 M Tris–HCl pH 7.5, 5 mM TCEP, 1%
DMSO).
To exclude any effects of the change in solvent conditions
on the protein, the apoprotein structures of crystals from
ammonium sulfate-based and PEG 8000-based crystal soaking
buffer were compared (see data sets in Table 1). These protein
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Figure 3
Binding mode of the aminothiazole ligand to E. coli KAS I protein. (a)
Electron density of the aminothiazole ligand (green) bound to the active
site of E. coli KAS I protein (grey). The 2Fo  Fc OMIT map (contoured
at 1) is shown in black; the Fo  Fc OMIT map (contoured at 2.5)i s
shown in orange. The OMIT map in the absence of inhibitor was
calculated using the ﬁnal reﬁned model. (b) Superposition of the binding
modes for the KAS I ligands thiolactomycin (cyan), cerulenin (gold) and
aminothiazole (green). For the representation of the protein, the
structure with bound aminothiazole ligand was used. The protein is
shown in surface representation, coloured according to atom type (C,
grey; N, blue; O, red; S, yellow). Monomer B of the dimer has been
removed, as well as side chains Met204 and Val270 of monomer A,t o
enable insight into the binding pocket. With an intact binding site, only
the acetyl moiety of the aminothiazole ligand is exposed to solvent. The
isoprenoid tail of thiolactomycin is buried in a hydrophobic pocket and is
not visible in this representation. The structure and binding mode of
cerulenin was taken from PDB entry 1fj8 (Price et al., 2001).structures are virtually identical. Near the active site a rotation
around 2 is observed for the Phe392 side chain in three of the
four chains in the asymmetric unit (monomers B, C and D),
which is indicative of the ﬂexibility of this lid of the active site
(see below). In monomer C, partial oxidation of the active-site
Cys163 to sulﬁnic acid was noted in the PEG 8000-based
crystal-soaking buffer. This is in contrast to the ammonium
sulfate conditions, where no indication of oxidation was
observed even after prolonged soaks. For subsequent soaks in
PEG 8000, 5 mM TCEP was added to the soaking buffer as a
reducing agent, which prevented oxidation of the active-site
Cys163.
Crystal soaking with the aminothiazole compound in PEG
8000 in the presence of TCEP yielded a 1.35 A ˚ data set
(Table 1) that revealed strong electron density for the bound
ligand at the active site in the Fo  Fc map (Fig. 3a). This data
set provides the highest resolution structure of E. coli KAS I
obtained to date, enabling unambiguous assignment of the
ligand-binding mode, of protein side-chain conformations
(such as Phe392) and the positioning of water molecules (such
as HOH2433) around the active site to aid in interpretation of
the structural information.
3.3. Description of the interactions of the aminothiazole with
the active-site residues
In the crystal structure of the complex of E. coli KAS I with
the aminothiazole compound, the ligand binds directly adja-
cent to the active-site residue Cys163 (Fig. 3a). The phenyl
ring stretches into the narrow fatty-acid binding pocket, which
is also the binding site for the inhibitor cerulenin. The thiazole
moiety reaches out towards the more spacious malonyl-ACP
binding pocket, which also harbours the thiolactomycin-
binding site (Fig. 3b). This binding mode at the centre of the
active site is distinct from those of the inhibitors thiolacto-
mycin and cerulenin.
The strong and speciﬁc interaction of the aminothiazole
with E. coli KAS I can primarily be attributed to three
features (Fig. 4). (i) A close but noncovalent interaction is
observed between the reactive active-site Cys163 and both the
thiazole S atom and the exocyclic amine N atom, with
distances of 3.3 and 3.1 A ˚ , respectively. This indicates strong
van der Waals interactions between the two S atoms and a
short NHS hydrogen bond between the Cys163 S atom and
the exocyclic amine N atom. Such hydrogen bonds between an
N and an S atom are not uncommon in proteins, but usually
have a distance of 3.4–3.7 A ˚ instead of 3.1 A ˚ (Gregoret et al.,
1991). Similarly, the two S atoms are also at a very close
distance: a survey of noncovalent protein–ligand interactions
indicates a preferred distance of two S atoms of 3.8 A ˚ ,w i t ha
distance of or below 3.3 A ˚ only seen in 1.5% of cases. These
close interactions are possibly a consequence of the bidentate
arrangement of the S and N atoms in the aminothiazole or of a
negative charge at the active-site Cys163. (ii) Several aromatic
amino acids show -stacking interactions (Meyer et al., 2003)
with the aromatic system of the aminothiazole. Phe392 is in a
parallel displaced arrangement with the thiazole ring. This
interaction stabilizes the conformation of the side chain of
Phe392, which is only poorly deﬁned in the apo form but
becomes well resolved in the complex structure. T-shaped
stacking interactions are found between Phe229 and the
thiazole ring, as well as between Phe201 and the phenyl ring of
the ligand. An additional -stacking interaction is observed
between the peptide bond of Ala162 and Cys163 and the
phenyl ring of the aminothiazole. (iii) The aminothiazole
molecule hasanexcellentshapecomplementarity tothe E.coli
KAS I active site and is almost completely buried. This is
particularly true for the phenyl moiety, which is in close
interaction with a number of hydrophobic residues: Phe201,
Leu335, Ala162, Met138, Val134 and the peptide backbone at
Gly106, Gly107 and Ala162. Met138 and Val134 are contrib-
uted by chain B of the dimer. A slight torsion of 20 away from
coplanarity is observed between the thiazole and the phenyl
ring (Fig. 3b), presumably to optimize the steric ﬁt of the
molecule to the active site. Additional hydrophobic inter-
actions are provided by the methyl substituent of the thiazole
ring with residues Phe201, Met204, Ala206 and Phe392.
The acetyl moiety of the aminothiazole ligand is signiﬁ-
cantly less well deﬁned than the remainder and no obvious
density is observed in the Fo  Fc map for the carbonyl O
atom and methyl C atom of the acetyl group
(Fig. 3a). The chemical structure and the
purity of the aminothiazole were checked
and veriﬁed using LC-MS and NMR spec-
troscopy. Consequently, the lack of electron
density must indicate rotational ﬂexibility of
the acetyl group, rather than a coplanar
conformation with the rest of the molecule.
Indeed, rather few interactions are found
between the protein and the acetyl group of
the ligand. Only the Ala206 side chain is in
proximity to the methyl C atom, with a 3.8 A ˚
distance;all other protein atoms are 4.5 A ˚ or
further away. The carbonyl O atom points
towards Thr300 and Thr302, but the
distances are too long for strong hydrogen-
bonding interactions (3.9 and 3.6 A ˚ ,
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Figure 4
Stereo diagram of the interactions of the aminothiazole ligand at the active site of E. coli KAS
I. The aminothiazole molecule is shown in green. Protein side chains or peptide bonds which
interact with the ligand are shown in grey. The backbone trace is indicated in cyan for
monomer A and in magenta for monomer B.respectively). Instead, a well deﬁned water molecule
(HOH2433) is hydrogen bonded to the side-chain O atoms of
Thr300 (2.9 A ˚ distance) and further water molecules in the
active site (Fig. 3a). If the acetyl group is positioned coplanar
with the remainder of the aminothiazole, the carbonyl O atom
would need to displace this water molecule, while being too far
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Figure 5
Conformational rearrangements in the active-site regions of E. coli KAS I. Superposition of monomer A (cyan) of the apo enzyme with (a) apo enzyme,
monomer B (magenta), showing the difference in the active-site geometry of the different monomers in the apo structure, (b) enzyme with bound
thiolactomycin, monomer A (gold), showing the induced ﬁt upon binding of thiolactomycin, and (c) enzyme with bound aminothiazole ligand, monomer
A (green), showing the absence of signiﬁcant conformational changes upon binding of the aminothiazole ligand.
away from Thr300 to provide a good alternative hydrogen-
bond interaction. If the acetyl group is instead in an out-of-
plane orientation, it avoids the energetic penalty of removing
this water molecule at the expense of reduced participation in
the delocalized electron system. The electron density around
the acetyl moiety of the ligand is thus interpreted as the
mutally exclusive presence of the water molecule HOH2433
(with an occupancy of 0.5) or a coplanar acetyl moiety of the
ligand (with an occupancy of 0.5).
3.4. Ligand-induced fit of the active-site conformation
In the E. coli KAS I apo structure, there are four molecules
in the asymmetric unit of the crystal with very similar overall
structure. However, the side chain of Phe392 and a neigh-
bouring loop (Asp268–Pro272, particularly Val270) near the
active site exhibit high temperature factors in all molecules
and differ in conformation (Fig. 5a). In monomer A, the side
chain of Phe392 is rotated around 1 such that the access to
the active site is open. This conformation can only be achieved
by an evasive movement of the neighbouring loop around
Val270. In contrast, in monomers B, C and D the phenyl ring
closes the active-site pocket together with the loop around
Val270.
Binding of thiolactomycin to monomer A results in an
induced ﬁt: Phe392 and the loop around Val270 in monomer A
are now in the same closed conformation (Fig. 5b) as seen in
the apo structures of the other monomers.
The binding of the aminothiazole ligand to monomer A,i n
contrast, does not change the active-site geometry: Phe392
and the loop around Val270 remain in the open conformation(Fig.5c) as in the apo structure of monomer A. This underlines
the perfect steric ﬁt of the aminothiazole ligand to the active-
site pocket. The advantageous -stacking interactions of
Phe392 and the thiazole ring result in an improved tempera-
ture factor of the side chain of Phe392 compared with the apo
structure. This interaction with an open active site is similar to
the binding of the natural inhibitor platensimycin to E. coli
KAS II, which requires the same arrangement of the equiva-
lent residue Phe400 in E. coli KAS II (Wang et al., 2006).
However, incubation with the aminothiazole ligand does
not result in an induced ﬁt for the other three monomers:
Phe392 and the loop around Val270 remain unchanged in the
closed conformation. The open active-site conformation
would be required to provide space for the thiazole ring and
its methyl substituent of the ligand and accordingly no ligand
can be detected at the active site in these three monomers.
From the crystal structure of the monomers and their inter-
actions, there is no obvious explanation why Phe392 and the
loop around Val270 are in the closed conformation in mono-
mers B, C and D and why the open conformation could not be
induced. We have to assume that the causes of the different
conformations of the monomers are hidden in the subtleties of
the overall protein structure.
3.5. Analysis of the binding mode of aminothiazole and
implications for drug discovery
The binding mode of the aminothiazole ligand is particu-
larly surprising with respect to its resemblance to thiolacto-
mycin (Fig. 1). Both ligands can be superimposed with high
shape similarity, bringing the S atoms into equivalent positions
(Fig. 6). From such ligand-based shape matching one would
have considered the aminothiazole compound to be a thio-
lactomycin analogue. In silico docking of the aminothiazole
compound into the apo structure of E. coli KAS I indeed
suggests an identical binding mode to that of thiolactomycin
for those protein monomers with the closed conformation of
Phe392 (B, C and D). In protein monomer A with the open
conformation of Phe392, however, the experimentally deter-
mined novel binding mode is correctly predicted. This
exempliﬁes the high predictive value that can be achieved by
computational methods for the understanding of protein–
ligand interactions, but also highlights the critical importance
of conformationally representative protein structure. Com-
putational methods reach their limits where ligand binding is
accompanied by signiﬁcant yet unknown changes in the
protein structure.
To evaluate whether a hit from a screen is a good starting
point for further optimization, the potency of the new ligand
should be weighted by its molecular mass. This is achieved by
calculation of the ligand efﬁciency: the free energy of binding
per non-H atom of the ligand (Hopkins et al., 2004). With a
binding afﬁnity of 25 mM and a molecular mass of 232, the
aminothiazole ligand has a ligand efﬁciency of 1.63 kJ mol
1
per non-H atom. This value is well within the range of
established drug molecules for drug targets. Furthermore, the
aminothiazole scaffold is chemically tractable and provides
options for synthetic chemistry modiﬁcations. The structural
information can immediately be used to support the rational
design of improved inhibitors. Owing to its central binding at
the active site, the ligand can expand into both the fatty-acid
and the malonyl-ACP binding pockets (Fig. 3b). The amino-
thiazole ligand therefore presents an excellent starting point
for lead-generation chemistry.
The phenyl moiety of the aminothiazole ligand occupies
part of the fatty acid-binding pocket with an excellent ﬁt. This
binding pocket offers the possibility of extending the ligand
with an aliphatic moiety similar to that observed in cerulenin
(Fig. 3b). However, proper positioning of the exit vector
would require signiﬁcant shifts of the phenyl moiety of the
ligand. This could be possible since the molecular basis for the
interaction is here primarily hydrophobic, with only a limited
contribution from directed interactions such as hydrogen
bonds. Consequently, a great variety of hydrophobic side
chains could ﬁt to this geometry and further exploration of the
fatty acid binding pocket could be an option to improve the
binding afﬁnity.
The methyl substituent on the thiazole ring offers a second
exit vector, but the space for extension is restricted by Met204
which is in proximity. The most promising exit vector is the
acetyl moiety of the ligand. It points directly into the large
water-ﬁlled malonyl-ACP binding pocket. Furthermore, its
structural environment indicates less than optimal interactions
with the protein (see above). One could therefore conceive
substituents that could properly substitute for water
HOH2433 as a hydrogen-bonding partner to Thr300 or
explore further hydrogen-bonding opportunities within the
polar malonyl-ACP binding pocket. A further obvious possi-
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Figure 6
Similarity of the aminothiazole compound to thiolactomycin. Shape-
matching superposition of the aminothiazole compound (red) with
thiolactomycin (blue) results in a high shape Tanimoto score of 0.73 and a
colour score of 0.32. The dashed circle indicates the exact superposition
of the S atoms of the two compounds.bility is a link from the aminothiazole to the isoprenoid moiety
of thiolactomycin in order to exploit its binding to the
hydrophobic side pocket of the malonyl-ACP binding site.
Furthermore, improvement of the physicochemical properties
of the molecule could be achieved by modiﬁcations at the
acetyl substituent. We therefore regard the aminothiazole
molecule as an excellent starting point for optimization to a
highly active and novel broadband antibacterial drug.
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